Skye Bioscience Inc.(US:SKYE) Newsfileยท2025-11-24 21:14Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and business practices [1][5]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between November 4, 2024, and October 3, 2025, and aims to address alleged misleading statements made by the company regarding its product, nimacimab [1][5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Skye Bioscience - The lawsuit claims that Skye Bioscience made materially false and misleading statements about its business operations and the effectiveness of nimacimab, which were overstated [5]. - Specific allegations include that nimacimab was less effective than claimed, and that the company's clinical, regulatory, and commercial prospects were misrepresented [5]. Group 3: Legal Representation - Investors interested in joining the class action can do so by contacting Rosen Law Firm through their website or phone [3][6]. - It is noted that no class has been certified yet, and investors are advised they may select their own counsel or remain absent from the class [7]. Group 4: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in terms of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].